Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
119 hedge funds and large institutions have $683M invested in Accelerate Diagnostics in 2017 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 14 reducing their positions, and 8 closing their positions.
264% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 14
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
39% more capital invested
Capital invested by funds: $493M → $683M (+$190M)
21% more funds holding
Funds holding: 98 → 119 (+21)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
20% less call options, than puts
Call options by funds: $7.96M | Put options by funds: $9.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$21.8M |
| 2 |
MGM
Miura Global Management
New York
|
+$14.1M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.7M |
| 4 |
Axa
Paris,
France
|
+$8.36M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$7.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$1.96M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$1.74M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.08M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$731K |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$606K |
AXDX Hedge Fund Activity: Q2 2017 in Review
119 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2017, worth a combined $683M — up 39% from $493M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AXDX positions and 8 closed out — a net gain of 21 holders — while 51 added to existing stakes and 14 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $21.8M. The largest seller was JP Morgan Private Wealth Advisors, cutting an estimated $1.96M.
- 119 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2017, up from 98 in Q1 2017.
- Funds reported $683M of Accelerate Diagnostics stock for Q2 2017, up 39% quarter-over-quarter.
- 29 funds opened new Accelerate Diagnostics positions in Q2 2017 and 8 closed out, a net change of +21 holders.
- The largest Accelerate Diagnostics buyer in Q2 2017 was Polar Capital, an estimated $21.8M added.
- The largest Accelerate Diagnostics seller in Q2 2017 was JP Morgan Private Wealth Advisors, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2017.